Sanofi licenses immune disease drugs from startup Earendil [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
French drugmaker Sanofi agreed to pay $125 million to startup Earendil Labs for two drug candidates designed to treat autoimmune and inflammatory bowel diseases. Under the terms of the deal announced Thursday , Earendil may receive as much as $1.72 billion in additional payments for reaching certain development and commercial goals, including $50 million described as a “near-term payment.” The startup will also be eligible for royalties if the drugs reach the market. The candidates, HXN-1002 and HNX-1003, are bispecific antibodies designed to engage two different proteins in the body involved in inflammation and immune cell activation. HXN-1002 is being developed for patients with ulcerative colitis and Crohn's disease. HXN-1003 has shown promise in preclinical models of colitis and skin inflammation, Earendil said. Dual-targeting antibodies have drawn considerable interest from pharmaceutical companies in recent years. But while much of the early activity centered around oncol
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation [Yahoo! Finance]Yahoo! Finance
- Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovationGlobeNewswire
- Weekly Recap: 13 Health Press Releases You Need to See [Yahoo! Finance]Yahoo! Finance
- Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases [Yahoo! Finance]Yahoo! Finance
- Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 12/15/25 - Form 6-K
- 12/12/25 - Form 6-K
- 12/3/25 - Form 6-K
- SNY's page on the SEC website